Simulations Plus Releases ADMET Predictor™ 6.5
Software Upgrade Increases Number of Predictive Models, Adds User Convenience Features
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NAS: SLP) , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 6.5 of its best-in-class ADMET Predictor™ software program for the prediction of molecular properties from structure.
Dr. Robert Fraczkiewicz, team leader for ADMET cheminformatics, said, "The release of version 6.5 is the culmination of many months of work by a number of our scientists and staff to add new functionalities and to respond to a variety of customer requests. The total number of enhancements is too many to list here; however, the major new features are:
18 new models that predict metabolic rate parameters for each atom in a molecule likely to be metabolized by certain Cytochrome P450 (CYP) enzymes
10 new models that predict mutagenicity (DNA changes) in Salmonella (an FDA standard test)
a new method that provides confidence levels for predictions from classification models
updated rules for ADMET Risk™ for metabolism and toxicity
a new model for human skin permeability
a new model for air-water partition coefficient (Henry's Law constant)
enhanced multidimensional graphics for easier data interpretation
a completely new software licensing package (FlexNet™ from Flexera Software) that is faster, more flexible, and more convenient to the end user compared to our previous method and is common in the pharmaceutical industry."
Dr. Fraczkiewicz continued, "We are especially pleased with the ability to predict the metabolic rate constants for each atom in a molecule. Prior models predicted these rate constants for the whole molecule but gave no indication of how strong the metabolism might be for different atoms. This new capability provides valuable information to design chemists. The new confidence levels for classification models is a response to customer requests and involved developing a new approach to calculating these values for artificial neural network ensembles."
John DiBella, vice president for marketing and sales of Simulations Plus, added, "Customers around the world have been waiting for this new release and we are pleased that it has finally passed all of our extensive testing with the many changes involved. The new FlexNet licensing software, already familiar to IT staff at many companies, will make licensing the software easier on both customers and our support staff. The additional predictive models make ADMET Predictor stand out even further from the competition, and the fantastic new graphics add sizzle to the steak."
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol "SLP." For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like "believe," "expect" and "anticipate" mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.
KEYWORDS: United States North America California
The article Simulations Plus Releases ADMET Predictor™ 6.5 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.